Editas Medicine highlights 2024 anticipated milestones, strategic priorities

Editas Medicine announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, at 4:30 p.m. PST. In his remarks, Dr. O’Neill will discuss several components of the Company’s strategic priorities and progress, including an unchanged focus on developing renizgamglogene autogedtemcel towards biologics licensing application and commercialization, building an in vivo pipeline, and increasing business development activities, including continuing to sublicense the Company’s foundational Cas9 and Cas12a gene editing technology. Dr. O’Neill will also discuss the Company’s anticipated 2024 milestones: Continue enrollment and dosing in the RUBY and EdiTHAL clinical trials of reni-cel, Initiate the adolescent cohort in the RUBY trial, Present a substantive clinical data set of sickle cell patients with considerable clinical follow-up in the RUBY trial in mid-2024 and by year-end 2024, Establish in vivo preclinical proof-of-concept for an undisclosed indication, and Derive revenue from the Company’s foundational IP, building on the recently announced license agreements with Vertex Pharmaceuticals and Vor Bio.